Cargando…

COVID-19 with rheumatic diseases: a report of 5 cases

The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chuanfang, Li, Chuanjing, Zhao, Tao, Yue, Jing, Yang, Fang, Yan, Yimin, Liu, Xiaoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220846/
https://www.ncbi.nlm.nih.gov/pubmed/32406001
http://dx.doi.org/10.1007/s10067-020-05160-x
_version_ 1783533246163714048
author Cheng, Chuanfang
Li, Chuanjing
Zhao, Tao
Yue, Jing
Yang, Fang
Yan, Yimin
Liu, Xiaoan
author_facet Cheng, Chuanfang
Li, Chuanjing
Zhao, Tao
Yue, Jing
Yang, Fang
Yan, Yimin
Liu, Xiaoan
author_sort Cheng, Chuanfang
collection PubMed
description The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged.
format Online
Article
Text
id pubmed-7220846
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-72208462020-05-14 COVID-19 with rheumatic diseases: a report of 5 cases Cheng, Chuanfang Li, Chuanjing Zhao, Tao Yue, Jing Yang, Fang Yan, Yimin Liu, Xiaoan Clin Rheumatol Case Based Review The coronavirus disease 2019 (COVID-19), the result of an infection with the new virus, SARS-CoV-2, is rapidly spreading worldwide. It is largely unknown whether the occurrence of COVID-19 in patients with rheumatic immune diseases has some specific manifestations, or makes them more prone to rapidly progress into severe COVID-19. In this case report, we describe the clinical features of 5 rheumatic immune disease patients with the concomitant presence of COVID-19. Amongst these patients, 4 had rheumatoid arthritis (RA) and 1 had systemic sclerosis (SSc). Two patients had a history of close contact with a COVID-19 patient. The age of the patients ranged between 51 and 79 years. Fever (80%), cough (80%), dyspnea (40%), and fatigue (20%) were the most common presenting symptoms. Laboratory investigations revealed leukopenia and lymphopenia in 2 patients. In all the patients, chest computerized tomography (CT) revealed patchy ground glass opacities in the lungs. During the hospital stay, the condition of two patients remained the same (i.e., mild COVID-19), two patients progressed to the severe COVID-19, and one patient worsened to the critically ill COVID-19. These patients were treated with antiviral agents for COVID-19, antibiotics for secondary bacterial infections, and immunomodulatory agents for rheumatic immune diseases. All the patients responded well, were cured of COVID-19, and subsequently discharged. Springer London 2020-05-14 2020 /pmc/articles/PMC7220846/ /pubmed/32406001 http://dx.doi.org/10.1007/s10067-020-05160-x Text en © International League of Associations for Rheumatology (ILAR) 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Based Review
Cheng, Chuanfang
Li, Chuanjing
Zhao, Tao
Yue, Jing
Yang, Fang
Yan, Yimin
Liu, Xiaoan
COVID-19 with rheumatic diseases: a report of 5 cases
title COVID-19 with rheumatic diseases: a report of 5 cases
title_full COVID-19 with rheumatic diseases: a report of 5 cases
title_fullStr COVID-19 with rheumatic diseases: a report of 5 cases
title_full_unstemmed COVID-19 with rheumatic diseases: a report of 5 cases
title_short COVID-19 with rheumatic diseases: a report of 5 cases
title_sort covid-19 with rheumatic diseases: a report of 5 cases
topic Case Based Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220846/
https://www.ncbi.nlm.nih.gov/pubmed/32406001
http://dx.doi.org/10.1007/s10067-020-05160-x
work_keys_str_mv AT chengchuanfang covid19withrheumaticdiseasesareportof5cases
AT lichuanjing covid19withrheumaticdiseasesareportof5cases
AT zhaotao covid19withrheumaticdiseasesareportof5cases
AT yuejing covid19withrheumaticdiseasesareportof5cases
AT yangfang covid19withrheumaticdiseasesareportof5cases
AT yanyimin covid19withrheumaticdiseasesareportof5cases
AT liuxiaoan covid19withrheumaticdiseasesareportof5cases